Alembic Pharma surges over 12% on USFDA approval for Cancer drug

Shares of Alembic Pharmaceuticals climbed over 12% after the company secured USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection. This milestone adds to its growing US generics portfolio and supports financial performance, with a reported 14% increase in net profit.

Markets